

**Health Economics
& Outcomes Research**

Health Economics & Outcomes Research Fellowships

2020



Novartis is a world leader in the research and development of products to protect and improve health and well-being.

Novartis was created in 1996 from the merger of the Swiss companies Ciba-Geigy and Sandoz. Novartis Pharmaceuticals is dedicated to discovering, developing, manufacturing, and marketing prescription drugs to prevent and cure diseases, to ease suffering and to enhance quality of life. Novartis' portfolio of products is directed toward cardiovascular, multiple sclerosis, immunology, hepatology, and dermatology, organ transplantation, ophthalmology, oncology and hematology, and other therapeutic areas.

Novartis, derived from the Latin *novae artes*, meaning "new skills," is committed to using new skills to improve health and well-being through innovative products and services. Recognizing an increasing need for outcomes information, resources and expertise, the Health Economics & Outcomes Research (HE&OR) departments at Novartis strive to be best-in-class in the generation of outcomes evidence that demonstrates value and optimizes patient access to Novartis products. This is accomplished through execution of burden

and cost-of-illness studies, economic evaluations alongside clinical trials, comparative effectiveness research, cost-effectiveness analyses, prospective observational studies such as effectiveness registries, retrospective claims database analyses and patient-reported outcomes research.



Purpose

The Health Economics & Outcomes Research Fellowship Program provides training and hands-on experience in a broad range of health economics, outcomes research and comparative effectiveness research (CER) opportunities. This 2-year program is structured to allow the Fellows to gain proficiency in the field of health economics, outcomes research and CER as conducted in academic, managed care, hospital, health policy and/or pharmaceutical industry settings.



Overview

Novartis Pharmaceuticals Corporation is pleased to offer three 2-year Health Economics & Outcomes Research Fellowship positions in 2020.


The objective of the first year is to educate the Fellow on general principles and methods applied in health economics and outcomes research. Concurrently, the Fellow will participate in ongoing outcomes research projects at the first-year Fellowship site. All Fellows will spend the second year of the Fellowship at the US-based headquarters of Novartis Pharmaceuticals Corporation located in East Hanover, New Jersey.

While at Novartis, “field-based” training will be undertaken as part of the Fellowship training. Fellows will participate in health economics and outcomes research projects and learn how a pharmaceutical manufacturer uses clinical, economic and humanistic data to support the development and commercialization of its products. The Fellowship positions differ by first-year site, requirements and type of experience offered. Each position is described in this brochure. Compensation includes a competitive stipend, basic medical insurance, holiday and vacation time, plus other benefits associated with each specific academic/managed care institution.

First-Year Fellowship Sites for 2-Year Programs:

- Baylor Scott & White Health, Temple, TX/
The University of Texas at Austin, Austin, TX
- Department of Pharmaceutical Health Services Research, University of Maryland, Baltimore, MD
- Jefferson College of Population Health, Thomas Jefferson University, Philadelphia, PA

Fellowship Alumni: Where Are They Now?



Contact

Please contact current Fellows for any site-specific questions (contact information provided on subsequent pages).

For inquiries regarding general application or interview process, please contact:

Vivian Herrera, DDS, MIA, MPH
Vice President
Health Economics and Outcomes Research
East Hanover, NJ
heor.fellowship@novartis.com



Novartis Pharmaceuticals Corporation/ Baylor Scott & White Health/ The University of Texas at Austin



Fellowship Sites & Preceptors

Baylor Scott & White Health

Paul Godley, PharmD, FASHP, BCPS, Director of Pharmacy, Ambulatory & Speciality Clinical Pharmacy Services, Temple, TX

The University of Texas at Austin College of Pharmacy

Karen Rascati, RPh, PhD, FAPhA, Graduate Advisor, Eckerd/Turley Centennial Endowed Professor, Austin, TX

Novartis Pharmaceuticals Corporation

Vivian Herrera, DDS, MIA, MPH, Vice President, Health Economics and Outcomes Research, East Hanover, NJ

Baylor Scott & White Health/The University of Texas

Baylor Scott & White is an integrated healthcare system in central Texas. The Scott & White Health Plan is a health maintenance organization that has over 400,000 members and is affiliated with the Baylor Scott & White Quality Alliance, the system's accountable care organization, which represents over 6,000 physicians. Baylor Scott & White is affiliated with the College of Medicine, Texas A&M University Health Science Center, and the College of Pharmacy, The University of Texas at Austin.

The Department of Pharmacy at Baylor Scott & White provides progressive and innovative pharmaceutical services in a variety of environments for all components of the institution. Included are clinical and distributive services for the hospital, clinic and health plan, as well as sponsorship of pharmaceutical care programs and ambulatory care clinics focusing on lipid, diabetes and anticoagulation management. Fellows will gain significant understanding of the key issues involved in pharmacy services provided by prescription benefits management and managed care organizations. The integrated character of the institution and the Department of Pharmacy provides significant opportunities for pharmacy practice, research and education.

The Health Outcomes and Pharmacy Practice Division, College of Pharmacy, The University of Texas at Austin, is one of the preeminent educational institutions for pharmacy education in the nation. The college is located in downtown Austin, and the Fellow is offered the option of pursuing the Master of Science degree in Pharmaceutical Sciences at the University of Texas, Austin. The degree would be granted at the end of the Fellowship provided that the required coursework and thesis have been completed. The recommended course of study is designed to assist the Fellow in coordinating required and recommended coursework along with the Fellowship requirements. However, the coursework is tailored based on individual interests, background and career goals. Additionally, the College has a Center for Pharmacoeconomics Studies that currently has eight researchers on staff and conducts a variety of outcomes research studies each year.

The unique nature of the Baylor Scott & White integrated healthcare system, combined with the pharmacoeconomic expertise at the College of Pharmacy, offers significant opportunity for individuals interested in the Novartis Fellowship experience.

Eligibility


Eligible candidates must have a doctorate in pharmacy or the combination of an undergraduate degree in pharmacy plus an advanced degree in health services research, public health, health policy, pharmacy, economics, medicine or other related area. Experience in, or at a minimum, exposure to some aspect of outcomes research, health economics or another related field of research is preferred.

Information

For questions or additional information, please contact:

Nina Kim, PharmD
Health Economics & Outcomes Research Fellow
Email: nina.kim@novartis.com

All questions regarding potential visa sponsorship should be directed to the collaborating institution.



Second-Year Fellow: Nina Kim, PharmD

Nina Kim is the second-year Health Economics & Outcomes Research (HE&OR) Fellow with Novartis Pharmaceuticals Corporation, Baylor Scott & White Health (BSWH), and the University of Texas at Austin.

Nina received her Doctor of Pharmacy degree from the University of Washington (UW) and her Bachelor's degree in Economics from the University of California, San Diego, with an interest in blending the two disciplines. She enters the Fellowship with complementary experiences in research, industry, managed care, pharmacy benefit management, regulatory, hospital, and community pharmacy.

Prior to the Fellowship, Nina conducted real-world evidence analyses using large claim databases to support commercial strategies under the Real World Informatics & Analytics team at Astellas Pharma. She also provided services in Immuno-Oncology for the Access Medical Information department at Bristol-Myers Squibb, where she developed dossier content for Opdivo® and Sprycel® by leveraging insights from cross-functional internal product strategy meetings and analyses on clinical, observational, and economic data. She also supported the Clinical Development team at Allergan in the development of phase II clinical trial scales. Additional experiences include placing 2nd in the national AMCP P&T Competition and serving multiple terms as a board member of the National AMCP Student Pharmacist Committee and the local UW AMCP chapter.

In her second year at Novartis, she supports the US HE&OR Immunology, Hepatology, and Dermatology therapeutic area by managing research studies via collaboration with cross-functional teams in concept development, protocol review, and functional planning. She also supports the team in the development of strategic messages for internal and external stakeholders. In addition, Nina is working towards earning a Master's degree in Pharmaceutical Sciences from the Health Outcomes Division at the University of Texas at Austin.



First-Year Fellow: Claire King, PharmD

Claire King is the first-year Health Economics & Outcomes Research (HE&OR) Fellow with Novartis Pharmaceuticals Corporation, Baylor Scott & White Health (BSWH), and the University of Texas at Austin.

Claire received her Doctorate of Pharmacy from the University of California, San Francisco (UCSF). She brings to the program professional experience in customer engagement, insurance claims analysis through her experience working with managed care markets, policy and market research, health economics, international health, and data analytics.

At CVS Health, Claire worked as an Advisor of Client Benefits, where she played an integral role in the implementation of Exchange, Commercial, Medicare, and Medicaid plan designs for a large health plan. Claire has held internships in medical communications at Dohmen Life Science Services, HE&OR at Allergan, managed care at Dymaxium Inc., and international health at the World Health Organization (WHO). At Allergan, she performed a systematic literature review on the impact of uterine fibroids on women's quality of life and presented her research at AMCP's Nexus conference. Her international health experience includes work assessing the pharmaceutical situation of Caribbean Community (CARICOM) governments using public procurement data to describe the feasibility of implementing a regional procurement database. Other relevant experience includes her role as president for UCSF AMCP chapter, a student representative on the University of California Student Health Insurance Plan Formulary Committee, and a member of AMCP's Student Pharmacist Committee.

During her first year, Claire conducts outcomes research for pharmaceutical companies and supports the Antibiotics Stewardship Committee and Specialty Task Force at BSWH. Her current projects include financial analysis of specialty medications and antibiotic prescribing trends to drive operational decisions at BSWH. In addition, Claire is working towards earning a Master's degree in Pharmaceutical Science from the Division of Health Outcomes and Pharmacy Practice at the University of Texas at Austin.

Novartis Pharmaceuticals Corporation/ University of Maryland School of Pharmacy



Fellowship Sites & Preceptors

University of Maryland School of Pharmacy

Linda Simoni-Wastila, BSPharm, MSPH, PhD, Professor, Department of Pharmaceutical Health Services Research, Baltimore, MD

Novartis Pharmaceuticals Corporation

Vivian Herrera, DDS, MIA, MPH, Vice President, Health Economics and Outcomes Research, East Hanover, NJ

The University of Maryland School of Pharmacy

The University of Maryland School of Pharmacy, founded in 1841, is the fourth oldest school of pharmacy in the nation. The School of Pharmacy is one of seven professional schools and a graduate school located at the University of Maryland Baltimore, a thriving center for health services practice and research. Through its education, research and service programs, the School of Pharmacy strives to improve the health and well-being of society by aiding in the discovery, development and optimal use of medicines. One of three departments within the School, the Department of Pharmaceutical Health Services Research (PHSR) aims to improve the health of diverse populations through pharmaceutical health services research, education, service and community outreach.

PHSR scholarship spans the disciplines of behavioral sciences, pharmacoeconomics, pharmacoepidemiology and policy. Fifteen faculty members conduct research sponsored by federal and state governmental agencies, foundations and the pharmaceutical industry. Work clusters around issues inherent in the Department's Centers: The Peter Lamy Center on Drug Therapy and Aging, and the Center on Drugs and Public Policy. Pharmaceutical Research Computing, a third Departmental center, provides computer programming, data management and analytic support to faculty, students and staff.

The Department houses numerous comprehensive databases, including the Chronic Condition Warehouse (CCW) 5% sample of Medicare beneficiaries linked to Part D data; the Medicare Current Beneficiary Survey; Medicaid and MAX data; and other proprietary and public data sets.

This two-year Fellowship focuses on the development of research skills relevant to health policy, with a particular focus on pharmaceutical policy. Fellows will spend the first year at the University of Maryland Baltimore honing research and policy skills and the second year at Novartis, where they will apply training and interests in an industry environment. Broad domains of interest include research focusing on medication management and outcomes in geriatric patients suffering multiple chronic illnesses, Medicare policy, long-term-care policy, mental health policy, patient-centered outcomes research and comparative effectiveness research. The successful applicant will work closely with a mentoring team to identify relevant research areas and training opportunities. The unique combination of rigorous academic training with industry experience in the second year will provide the Fellow considerable experience to conduct policy-relevant health services and outcomes research.

Eligibility

Eligible candidates should have an advanced degree in health services research, public health, economics, epidemiology, pharmacy, pharmacy administration or a related discipline. A background in pharmacy or medicine and experience in outcomes research, health economics or another related field of research is preferred. Candidates must have excellent written and verbal communication skills.

Information

For questions or additional information, please contact:

Ngan Pham, PharmD
Health Economics & Outcomes Research Fellow
Email: ngan.pham@novartis.com

All questions regarding potential visa sponsorship should be directed to the collaborating institution.



Second-Year Fellow: Ngan Pham, PharmD

Ngan Pham is the second-year Health Economics & Outcomes Research (HE&OR) Fellow with the University of Maryland School of Pharmacy and Novartis Pharmaceuticals Corporation.

Ngan received his Doctor of Pharmacy degree and Certificate in Biomedical Regulatory Affairs from the University of Washington School of Pharmacy, where he also completed additional graduate-level coursework in cost-effectiveness research, managed care, and health policy. During pharmacy school, Ngan was president of the Student Chapter of the Academy of Managed Care Pharmacy (AMCP) and led a collaboration between AMCP and the graduate chapter of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR). Additionally, he was involved in several research projects with HE&OR professors at the School of Pharmacy, including an economic evaluation of psoriasis for the Institute for Clinical and Economic Review and a cost-utility analysis of biologics for the treatment of psoriatic arthritis.

As a first-year Fellow at the University of Maryland, Ngan focused on geriatric outcomes and health policy work under the tutelage of Dr. Linda Wastila. He supported several projects, including an evaluation of a novel pharmacy naloxone training program in Maryland and a study on the association of medical cannabis laws and psychotherapeutic drug utilization in older adults. He took additional coursework in biostatistics and research methods, where he completed a study on the healthcare resource utilization and costs of patients with hepatocellular carcinoma. As a Novartis Fellow, Ngan led a budget impact analysis of adding a mobile health app for diabetes to a commercial formulary.

In his second year at Novartis, Ngan supports the US HE&OR Respiratory and Ophthalmology business units. He works cross-functionally to support launch and marketed products through collaboration with internal and external stakeholders in strategic planning, concept development, and study management. He is currently completing a Master of Science in International Health Technology Assessment, Pricing, and Reimbursement from the University of Sheffield.



First-Year Fellow: Eric Hsiao, PharmD

Eric Hsiao is the first-year Health Economics & Outcomes Research (HE&OR) Fellow with the University of Maryland School of Pharmacy and Novartis Pharmaceuticals Corporation.

Eric graduated with his PharmD from the University of the Sciences in Philadelphia. Eric stimulated his interest in research through supporting studies on infective endocarditis and intravenous drug abuse and by completing a minor in biostatistics. His passion for pharmacoeconomics and health outcomes was ignited after he completed a PhD-level course in health policy.

During his final year in pharmacy school, Eric rotated at Peloton Advantage where he supported teams in producing deliverables for hypophosphatasia and Wilson's disease portfolios for pharma clients. He also rotated at Novartis where he completed projects on ophthalmology, neuroscience, and rheumatology.

During his first year of Fellowship, Eric will build his capabilities in research methods in the classroom and complete directed self-study in topics in applied pharmacoeconomics and in biostatistics.

At the University of Maryland, Eric currently supports Dr. Linda Wastila and her team in research involving older adults, opioid dependence, and cannabis policy. He is currently contributing to research regarding the effects of prescription drug monitoring programs on appropriate opioid prescribing and use, the current status of cannabis laws, policies, and regulations across the United States, and the potential relationship of cannabis accessibility to rate of opioid utilization. As part of Dr. Linda Wastila's team, Eric will also be supporting research conducted at the Peter Lamy Center on Drug Therapy and Aging, where researchers are currently investigating ways to reduce antipsychotic overuse in long-term care facilities.

Novartis Pharmaceuticals Corporation/ Thomas Jefferson University, Jefferson College of Population Health



Fellowship Sites & Preceptors

Thomas Jefferson University

Vittorio Maio, PharmD, MS, MSPH, Research Professor, Director, Health Economics and Outcomes Research Fellowship, Jefferson College of Population Health, Thomas Jefferson University, Philadelphia, PA

Novartis Pharmaceuticals Corporation

Vivian Herrera, DDS, MIA, MPH, Vice President, Health Economics and Outcomes Research, East Hanover, NJ

College of Population Health, Thomas Jefferson University

Established in 2008, the Jefferson College of Population Health (JCPH) is one of six colleges that comprise Thomas Jefferson University, founded in 1824 as Jefferson Medical College. JCPH builds upon the 18-year history of Jefferson's Department of Health Policy and specializes in all key areas of population health—public health, health policy, healthcare quality and safety, and applied health economics and outcomes research (AHEOR). The College has one of the oldest and most established outcomes research Fellowship programs in the country. To date, over 50 individuals have completed JCPH Fellowships and have successfully pursued careers in all sectors of the healthcare industry, including government, pharmacy, insurers and consulting.

During the first year, the Fellow will work in JCPH at the University's Philadelphia Center City campus and be assigned to manage specific outcomes research projects. As a member of the JCPH research team, s/he has the opportunity to attend and present at research meetings, journal clubs, Population Health Forums and sponsored educational programs. S/he may also contribute to any one of several graduate level classes taught by JCPH faculty in the College's public health, AHEOR, health policy, healthcare quality and safety, population health intelligence and population health graduate programs. The Fellow will develop writing skills through completion of a writing seminar, peer review of continuing education articles and authorship of manuscripts for publications edited by *American Journal of Medical Quality*, *Population Health Management*, and *Population Health Matters*.

Networking is also an important activity during the first year. The Fellow will interact with decision makers from both within the University and from a broad variety of organizations, including pharmaceutical and device manufacturers, health plans and other health-related employers. The Fellow will regularly meet with JCPH faculty and staff to discuss research projects and academic experiences, and s/he will be assigned a faculty mentor to coach him/her during the first year. Completion of master's level coursework through JCPH is a formal component of this Fellowship and serves to develop the knowledge and skills required for health economics and outcomes research. The Fellow has the option to complete a fully supported graduate Certificate or Master of Science degree program in public health, population health, population health intelligence, health policy or applied health economics and outcomes research.

The second year of training will take place at Novartis, located in East Hanover, New Jersey. During this time, under the guidance of a Novartis preceptor, the Fellow will work directly with the HE&OR department at Novartis for a period of one year in order to further their educational objectives by gaining applied experience in health economics and outcomes research. In addition to project work, the Fellow will participate in meetings to share his or her work and further develop networking and presentation skills.

Eligibility

Eligible candidates should have an advanced degree in health services research, public health, economics, epidemiology, pharmacy, pharmacy administration or a related discipline. A background in pharmacy or medicine and experience in outcomes research, health economics or another related field of research is preferred. Candidates must have excellent written and verbal communication skills.

Information

For questions or additional information, please contact:

Karishma Shelley, PharmD
Health Economics & Outcomes Research Fellow
Email: karishma.shelley@novartis.com

All questions regarding potential visa sponsorship should be directed to the collaborating institution.



Second-Year Fellow: Karishma Shelley, PharmD

Karishma Shelley is a second-year Health Economics & Outcomes Research (HE&OR) Fellow with the Jefferson College of Population Health (JCPH) and Novartis Pharmaceuticals Corporation.

Karishma received her Doctor of Pharmacy degree from The University of the Sciences (USciences) in 2018. Prior to the fellowship, Karishma gained valuable experience in managed care, pharmaceutical consulting, and academic research by supporting the Department of Defense formulary, creating value propositions, and conducting real-world utilization research. She is a published author in the Journal of Pharmacotherapy on HIV pre-exposure prophylaxis. Her pursuit of a career in HE&OR stems from her interest in further understanding the US healthcare landscape.

During her first year at JCPH, Karishma conducted research projects utilizing retrospective databases, large claims databases, and patient-reported survey data. Karishma gained experience applying the principles of outcomes research by leading studies involving the oncology care model, childhood adversity, sunshine reporting, potentially inappropriate prescribing in the elderly, and value-based frameworks. She had the opportunity to present at local and national conferences to understand population health regionally and within the landscape of the US healthcare system.

In her second year of the Fellowship, she supports the US HE&OR Cardiovascular and Neuroscience business units. She is currently involved in post-approval and pre-launch research dependent on strategic alignment with internal and external stakeholders. Her research consists of retrospective claims database analyses, qualitative research, and economic modeling. Karishma is also continuing coursework towards earning a Master's degree in Applied Health Economics & Outcomes Research from JCPH.



First-Year Fellow: Laetitia N'Dri, PharmD

Laetitia N'Dri is a first-year Health Economics & Outcomes Research (HE&OR) Fellow with the Jefferson College of Population Health (JCPH) and Novartis Pharmaceuticals Corporation.

Laetitia received her Doctor of Pharmacy degree from the University of Maryland School of Pharmacy, Baltimore, in May 2019. Her interest in Health Economics & Outcomes Research stems from her passion for public health, patient-reported outcomes, and economic modeling. During her first year of pharmacy school, Laetitia started working at the UMB Department of Pharmaceutical Health Services Research as a Research Assistant. There, she completed several projects including discrete choice and best-worst scaling experiments, patient-centered outcomes research, and patient-driven value assessments. Additionally, Laetitia was involved in multidisciplinary research with the UMB School of Nursing to assess environmental impacts on adolescents' mental health, and she also collaborated with the University of Washington to conduct a cost-utility analysis on malaria prophylactic treatment.

During her fourth year of pharmacy school, Laetitia obtained additional exposure in HEOR through her rotations at Bioverativ, a Sanofi Company, and MedImmune/AstraZeneca where she presented on topics such as ICER, real-world evidence generation, and population pharmacokinetics.

Furthermore, Laetitia had the opportunity to publish two peer-reviewed manuscripts during her pharmacy school career and won an FDA national competition aiming at improving healthcare interventions for CAR T-cell therapy. As she embarks on this new journey with the JCPH Fellowship, Laetitia aspires to apply her multidisciplinary and diverse background in HE&OR to promote access, to provide safe and effective patient care, and to improve outcomes.

Previous Fellows

Neetu Agashivala, MS

Executive Director, Health Economics & Outcomes Research,
Novartis Pharmaceuticals Corporation

Lauren Bartolome, PharmD

Senior Manager, Health Economics & Outcomes Research,
Pfizer

Kelly Fee Bell, PharmD, MSPH

Director, Value Evidence and Outcomes,
GlaxoSmithKline

William Boyko, PharmD

Clinical Account Executive,
Express Scripts

Cat Bui, PharmD

Director, Health Economics & Outcomes Research,
AbbVie Pharma US, Inc.

Scott Bull, PharmD

Director, Clinical Development,
Johnson & Johnson Pharmaceutical Research & Development

Beilei Cai, PhD, MA

Associate Director, Health Economics and Outcomes Research,
Novartis Oncology

Jane Chang, MPH

Director, Global Outcomes & Evidence,
Pfizer

Michelle Choi, PharmD

Manager, Health Economics and Outcomes Research, AbbVie

Paul C. Cockrum, PharmD, DPh

National Director, Field HEOR,
Celgene

QuynhChau Doan, MS, RPh, PhD

Medical Outcomes Science Liaison,
AbbVie

Batul Electricwala, PhD

Associate Director, Health Economics & Outcomes Research,
Novartis Pharmaceuticals Corporation

John Fastenau, PhD, MPH, RPH

Senior Director, Patient Reported Outcomes,
Janssen Pharmaceutical Companies of Johnson & Johnson

Feride Frech-Tamas, PhD, MPH

Executive Director, Epidemiology and Outcomes Research,
Lexicon Pharmaceuticals

Rahul Garg, PhD

Assistant Professor,
Chicago State University

Joseph Goble, PharmD

Senior Scientific Account Lead, Real World Value & Evidence, Janssen Pharmaceutical Companies of Johnson & Johnson

Boris Gorsh, PharmD

Director, Health Economics & Outcomes Research,
Pfizer

Geneen Graber, PharmD

President and CEO,
Dr. G's Pharmacy

Bill Grant, PhD

Associate Professor of Economics,
College of Business,
James Madison University

Amy Grogg, PharmD

Senior Vice President,
Strategy and Commercialization,
AmerisourceBergen Specialty Group

Kristy Hanson, PharmD, MS

Scientific Consultant,
United BioSource Corporation

Peter Hur, PharmD, MBA

Associate Director, Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation

Tom Karagiannis, PharmD, MS

Senior Manager, Global Market Access & Pricing,
AbbVie

Jennifer Kim, PharmD

Director, Global Price and Reimbursement,
AstraZeneca

John Kim, PharmD

Reimbursement Director, Global Pricing & Market Access, Amgen

Yoona Kim, PharmD, PhD

Head of Clinical Modeling and Analytics,
Proteus Digital Health

John Ko, PharmD, MS

Associate Director, Global Value & Evidence Strategy Lead,
Alnylam

Amy Law, PharmD, MS

Director, Medical Affairs Research,
Intercept Pharmaceuticals

Jackie Lu, PharmD, MS

General Manager, Canada,
Pacira Pharmaceuticals

Mario Luong, PharmD, MPH

Manager of Operations,
UnitedHealth Group

Jeannie Menz, PharmD

Associate Director, Medical Information and Communication,
Novartis Pharmaceuticals Corporation

Gilbert C. Ngan

Pharmacist: Part D Benefits Analyst,
CMS

Lina Nol-Heiring, MBA, RPh

Dermatology Sales Professional,
Valeant Pharmaceuticals

Engels Obi, PhD

Director, Global Outcomes Research,
Merck

Jacqueline B. Palmer, PharmD

Associate Medical Director,
Novartis Pharmaceuticals Corporation

Jina Park, PharmD

Director, Health Economics
& Outcomes Research,
Novartis Pharmaceuticals Corporation

Hoa T. Pham

Medical Science Director,
ZS Pharma, Inc.

Craig Plauschinat, PharmD, MPH

Senior Director, Evidence Based Medicine,
Sanofi

Shibani Pokras, MPH

Senior Director, Value Evidence Leader,
GlaxoSmithKline

Karim Prasla, PharmD, MS

Vice President, Clinical Outcomes
Analytics and Research,
Magellan Health Services

Karina Raimundo, MS

Principal Health Economicst, Evidence for Access,
Genentech, Inc.

Swetha Raparla

Analytics Consultant,
Cigna

David Ray, PharmD, MBA, MPH

Director, Health Economics & Outcomes Research,
Ipsen Biopharmaceuticals

Rahul Sasané, PhD, MS, BPharm

Head, Health Economics & Outcomes Research
& Real World Evidence,
Cerevel Therapeutics, LLC

Veronica Sendersky, PharmD

RWE Regional Solutions Lead,
Excellent Pharma Consulting

Hemal Shah, PharmD

President/Founder,
Value Matters, LLC

Slaven Sikirica, MS

Associate Director, Health Economics
& Outcomes Research,
Novartis Pharmaceuticals Corporation

Anh Singhanian, PharmD

Director, Key Account, Market Access,
Insmed Incorporated

Liz Stanley Smart, MPH

Associate Director, Health Economics
& Outcomes Research,
Boehringer Ingelheim

Bhavini Patel Srivastava, BSPS, MS

Manager, Health Economics
& Outcomes Research,
Pharmacyclics

Kangho Suh, PharmD, MS

Assistant Professor,
University of Pittsburgh

Dusica Tasic

Health Economics Manager, Global Marketing,
GE Healthcare

Devi Thaker, PharmD

Director, PharmacoAnalytics,
GlaxoSmithKline

Melody Tran, PharmD, MS

Medical Outcomes Liaison,
Abbott Laboratories

Yuen Tsang, PharmD, MPH

Senior Medical Liaison, Managed
Markets and Health Economics
& Outcomes Research,
Actelion Pharmaceuticals

Stuart Turner, BPharm, MPH

Director, Real World Evidence,
Novartis Pharmaceuticals Corporation

Stefan Varga, PharmD

Associate Director, Outcomes Research,
Merck

Ashok Vegesna, PharmD, MS

Director, Medical Access,
Novartis Pharmaceuticals Corporation

Joel Wallace, PharmD, MPH, MBA

Senior Leader, External Affairs,
Chugai Pharmaceutical Co, LTD

Pin Xiang, PharmD

Senior Manager, Global Health Economics
& Outcomes Research
Amgen

Esther Yi, PharmD

Senior Manager, Health Economics
& Outcomes Research,
Novartis Pharmaceuticals Corporation

Krista Yokoyama, PharmD

Senior Manager, Pharmacy Analytics,
Blue Shield of California

Health Economics & Outcomes Research Fellowship Application Form

Please type or print

Date _____

Name: _____
Last First MI

Address: _____
Street City State Zip Code

Phone: _____
Primary Secondary

Email: _____

Undergraduate and Graduate Degree(s) (date received or expected):

2-Year Programs (Preferred Degrees: PharmD, PhD, MS)

Please rank your site(s) of interest in order of priority (1 as highest priority):

_____ Baylor Scott & White Health/The University of Texas at Austin/Novartis Pharmaceuticals Corporation

_____ The University of Maryland/Novartis Pharmaceuticals Corporation

_____ Thomas Jefferson University College of Population Health/Novartis Pharmaceuticals Corporation

Application Materials Required

- Application form
- Curriculum vitae
- Three letters of recommendation (must be forwarded directly by the authors of these letters)
- Unofficial academic transcript (Official transcript required once accepted and must be forwarded directly from the Registrar's Office)

Please email or send the required application materials to:

Health Economics & Outcomes Research Fellowship
One Health Plaza, Building 125/4422C, East Hanover, NJ 07936
Email: heor.fellowship@novartis.com

